X4 PHARMACEUTICALS, INC (XFOR) Operating Margin
- Operating margin · 12 months: Value -554.71%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -554.71% | Operating income / revenue. Period ending 2026-06-30. $-87.91M ÷ $15.85M × 100 ≈ -554.71% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -87.91M USD | Operating Income (Loss) |
| Revenue | 15.85M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 66.39M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-87.91M | $15.85M | (m) | $66.39M | (m) | -554.71% |
| 2026-03-31 | $-97.75M | $9.01M | (m) | $69.66M | (m) | -1084.38% |
| 2025-12-31 | $-86.88M | $35.11M | (m) | $72.72M | (m) | -247.44% |
| 2025-09-30 | $-98.90M | $33.98M | (m) | $75.90M | (m) | -291.06% |
| 2025-06-30 | $-105.89M | $32.77M | (m) | $77.74M | (m) | -323.09% |
| 2025-03-31 | $-8.55M | $31.36M | (m) | $80.30M | (m) | -27.28% |
| 2024-12-31 | $-36.40M | $2.56M | (m) | $81.64M | (m) | -1423.58% |
| 2024-09-30 | $-25.89M | (m) | (m) | $75.21M | (m) | (m) |
| 2024-06-30 | $-18.60M | (m) | (m) | $75.12M | (m) | (m) |
| 2024-03-31 | $-115.51M | (m) | (m) | $69.81M | (m) | (m) |
| 2023-12-31 | $-107.52M | (m) | (m) | $72.02M | (m) | (m) |
| 2023-09-30 | $-107.90M | (m) | (m) | $75.76M | (m) | (m) |
| 2023-06-30 | $-100.84M | (m) | (m) | $70.79M | (m) | (m) |
| 2023-03-31 | $-95.61M | (m) | (m) | $69.01M | (m) | (m) |
| 2022-12-31 | $-87.57M | $0.00 | (m) | $61.06M | (m) | (m) |
| 2022-09-30 | $-91.05M | (m) | (m) | $54.21M | (m) | (m) |
| 2022-06-30 | $-90.01M | (m) | (m) | $53.28M | (m) | (m) |
| 2022-03-31 | $-88.44M | (m) | (m) | $52.66M | (m) | (m) |
| 2021-12-31 | $-85.11M | $0.00 | (m) | $50.65M | (m) | (m) |
| 2021-09-30 | $-73.71M | $0.00 | (m) | $50.78M | (m) | (m) |
| 2021-06-30 | $-71.57M | $0.00 | (m) | $48.98M | (m) | (m) |
| 2021-03-31 | $-67.23M | $0.00 | (m) | $45.13M | (m) | (m) |
| 2020-12-31 | $-59.87M | $3.00M | (m) | $41.93M | (m) | -1995.80% |
| 2020-09-30 | $-53.09M | (m) | (m) | $36.70M | (m) | (m) |
| 2020-06-30 | $-53.09M | (m) | (m) | $33.91M | (m) | (m) |
| 2020-03-31 | $-51.85M | (m) | (m) | $33.42M | (m) | (m) |
| 2019-12-31 | $-51.70M | (m) | (m) | $30.16M | (m) | (m) |
| 2019-09-30 | $-65.68M | (m) | (m) | $38.42M | (m) | (m) |
| 2019-06-30 | $-57.25M | (m) | (m) | $35.99M | (m) | (m) |
| 2019-03-31 | $-50.21M | (m) | (m) | $31.89M | (m) | (m) |
| 2018-12-31 | $-45.88M | $3.50M | (m) | $30.98M | (m) | -1311.00% |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-36.13M | (m) | (m) | $28.13M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-24.35M | (m) | (m) | $17.83M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |